- PYR-41
-
- $33.00 / 2mg
-
2026-03-13
- CAS:418805-02-4
- Min. Order:
- Purity: 99.24%
- Supply Ability: 10g
- PYR 41
-
- $1.00 / 1g
-
2019-12-26
- CAS:418805-02-4
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 200kg
|
| Product Name: | PYR 41 | | Synonyms: | PYR 41;4-[4-[(5-Nitro-2-furanyl)methylene]-3,5-dioxo-1-pyrazolidinyl]benzoic acid ethyl ester;Benzoic acid, 4-[4-[(5-nitro-2-furanyl)methylene]-3,5-dioxo-1-pyrazolidinyl]-, ethyl ester;4-[4-[(5-Nitro-2-furanyl)methylene]-3,5-dioxo-1-pyrazolidinyl]benzoic acid ethyl ester PYR 41;PYR 41 4-[4-[(5-Nitro-2-furanyl)methylene]-3,5-dioxo-1-pyrazolidinyl]benzoic acid ethyl ester;4[4-(5-Nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl]-benzoic acid ethyl ester;PYR 41, >=98%;CS-1129 | | CAS: | 418805-02-4 | | MF: | C17H13N3O7 | | MW: | 371.3 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 418805-02-4.mol |  |
| | PYR 41 Chemical Properties |
| Melting point | 228 - 235°C | | density | 1.486±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO at 5mg/ml with warming | | form | powder | | pka | 7.43±0.20(Predicted) | | color | red to brown | | Sensitive | Light Sensitive | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 week. | | InChI | InChI=1S/C17H13N3O7/c1-2-26-17(23)10-3-5-11(6-4-10)19-16(22)13(15(21)18-19)9-12-7-8-14(27-12)20(24)25/h3-9H,2H2,1H3,(H,18,21) | | InChIKey | ARGIPZKQJGFSGQ-LCYFTJDESA-N | | SMILES | C(OCC)(=O)C1=CC=C(N2C(=O)C(=CC3=CC=C([N+]([O-])=O)O3)C(=O)N2)C=C1 |
| Hazard Codes | Xn | | Risk Statements | 22-43 | | Safety Statements | 36/37 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral
Skin Sens. 1 |
| | PYR 41 Usage And Synthesis |
| Description | Pyr41 (418805-02-4) inhibits ubiquitin activating enzyme E1 (>60% inhibition at 10 μM) with little or no activity against E2 or E3. Cell permeable | | Uses | PYR 41 is an irreversible and cell-permeable UBE1 inhibitor. | | Definition | ChEBI: PYR-41 is an ethyl ester resulting from the formal condensation of the carboxy group of 4-{4-[(5-nitrofuran-2-yl)methylidene]-3,5-dioxopyrazolidin-1-yl}benzoic acid with ethanol. It is an irreversible and cell-permeable inhibitor of ubiquitin-activating enzyme E1. It has a role as an EC 6.2.1.45 (E1 ubiquitin-activating enzyme) inhibitor and an antineoplastic agent. It is an ethyl ester, a member of furans, a C-nitro compound, a member of pyrazolidines and a benzoate ester. | | Biochem/physiol Actions | PYR-41 is a cell permeable inhibitor of Ubiquitin activating enzyme (E1) with little or no activity against E3, E2, or caspase enzymatic activity. | | in vitro | in addition to blocking ubiquitylation, pyr-41 was found to increase total sumoylation in cells. pyr-41 could attenuate cytokine-mediated nuclear factor-kbactivation. this correlated with inhibition of nonproteasomal ubiquitylation of traf6, which is important to ikbkinase activation. pyr-41 also prevented the downstream ubiquitylation and proteasomal degradation of ikba. moreover, pyr-41 has demonstrated effective uae e1 inhibition as well as some off-target inhibition of the other ubiquitin regulatory enzymes and signal-transducing proteins, suggesting it is a nonspecific inhibitor [1]. | | storage | Store at -20°C | | References | [1] YILI YANG. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics.[J]. Cancer research, 2007, 67 19: 9472-9481. DOI:10.1158/0008-5472.can-07-0568
[2] LIXIN MI. Cancer preventive isothiocyanates induce selective degradation of cellular alpha- and beta-tubulins by proteasomes.[J]. The Journal of Biological Chemistry, 2009, 284 25: 17039-17051. DOI:10.1074/jbc.m901789200
[3] TOMOHIKO MAEHAMA. Nucleolar stress induces ubiquitination-independent proteasomal degradation of PICT1 protein.[J]. The Journal of Biological Chemistry, 2014, 289 30: 20802-20812. DOI:10.1074/jbc.m114.571893 |
| | PYR 41 Preparation Products And Raw materials |
|